May. 13 at 2:22 PM
$ADTX
• Market may be missing that ADTX is no longer just the old ADTX story — Ignite looks more like a quasi-merger style asset injection with a
$36M transaction attached to it.
• The Series A-2 preferred converts at ~
$2.73, not at current 7-10c prices.
• Based on current filings, the conversion economics cannot simply reset overnight into a toxic death spiral.
• Potential lower conversion/reset mechanics appear tied to future shareholder approval timing around spring 2027 — not immediate dumping at current prices.
• Dana-Farber connection + real oncology/proteomics platform + Medicare/CPT infrastructure makes this far more credible than a typical shell narrative.
• At these market cap levels, the disconnect between current valuation and the structure of the Ignite transaction looks extreme.
